Skip to Main Content

Paper Details

Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis.
J Pediatr
49
2018
PVS, congenital heart disease, imatinib mesylatewith, lung disease, multivessel intraluminal pulmonary vein stenosis, neoproliferative myofibroblast-like cells, patients, tyrosine, tyrosine kinase, tyrosine kinase receptor
Angiogenesis Inhibitors, Bevacizumab, Child, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Imatinib Mesylate, Male, Prospective Studies, Protein Kinase Inhibitors, Stenosis, Pulmonary Vein, Treatment Outcome
Author NameAffiliation
Ryan CallahanBoston Children's Hospital and Harvard Medical School
Mark W KieranDana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School
Mark W KieranDana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School
Christopher W BairdBoston Children's Hospital and Harvard Medical School
Steven D ColanBoston Children's Hospital and Harvard Medical School
Kimberlee GauvreauBoston Children's Hospital and Harvard Medical School
Christina IrelandBoston Children's Hospital and Harvard Medical School
Audrey C MarshallFloating Hospital for Children at Tufts Medical Center
Laureen M Senauniversity of massachusetts amherst Memorial Medical Center
Sara O VargasBoston Children's Hospital and Harvard Medical School
Kathy J JenkinsBoston Children's Hospital and Harvard Medical School
  • 1 - 11

Datasets

Release 1.2